Court Restrains Dr Reddy’s In Indian Belviq Case
Executive Summary
An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.
You may also be interested in...
As Belviq Goes Off India Market, Patent Case May Fizzle
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.
Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India
Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.